Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.
Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice. When OFLX (3 mg/mouse) was given to infected mice in combination with RMP (0.01 mg/mouse) by gavage once daily six times per week, from day 31 to day 80 postinfection, a significant combined effect was observed. This study demonstrates the possibility of using OFLX in multidrug regimens for the clinical control of bacilliferous leprosy patients.
Department of Microbiology and Immunology, Shimane Medical University, Izumo, Japan.
H
H
Tomioka
H
H
Saito
D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D015242:Ofloxacin / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use*
D015363:Quinolones; D015242:Ofloxacin; D012293:Rifampin